ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company is involved in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump, a device for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Japan. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone978-646-1400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$593.75 million
Profitability
Miscellaneous
Employees1,143
OptionableOptionable
ABIOMED (NASDAQ:ABMD) Frequently Asked Questions
What is ABIOMED's stock symbol?
ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."
How were ABIOMED's earnings last quarter?
ABIOMED, Inc. (NASDAQ:ABMD) issued its quarterly earnings data on Thursday, November, 1st. The medical equipment provider reported $1.09 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.73 by $0.36. The medical equipment provider earned $181.78 million during the quarter, compared to analysts' expectations of $175.41 million. ABIOMED had a return on equity of 20.09% and a net margin of 27.60%. The company's revenue for the quarter was up 36.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.54 EPS. View ABIOMED's Earnings History.
When is ABIOMED's next earnings date?
What guidance has ABIOMED issued on next quarter's earnings?
ABIOMED updated its FY 2019 earnings guidance on Monday, January, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $780-780 million, compared to the consensus revenue estimate of $773.55 million.ABIOMED also updated its Q3 2019 guidance to EPS.
What price target have analysts set for ABMD?
8 Wall Street analysts have issued 12-month price targets for ABIOMED's shares. Their forecasts range from $280.00 to $480.00. On average, they anticipate ABIOMED's share price to reach $391.6250 in the next twelve months. This suggests a possible upside of 17.3% from the stock's current price. View Analyst Price Targets for ABIOMED.
What is the consensus analysts' recommendation for ABIOMED?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ABIOMED in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ABIOMED.
Has ABIOMED been receiving favorable news coverage?
Headlines about ABMD stock have been trending very positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. ABIOMED earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of ABIOMED's key competitors?
Some companies that are related to ABIOMED include Boston Scientific (BSX), Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hill-Rom (HRC), Haemonetics (HAE), Penumbra (PEN), ICU Medical (ICUI), Insulet (PODD), Novocure (NVCR), Globus Medical (GMED), Integra Lifesciences (IART) and Cantel Medical (CMD).
Who are ABIOMED's key executives?
ABIOMED's management team includes the folowing people:
- Mr. Michael R. Minogue, Chairman, CEO & Pres (Age 52)
- Dr. David M. Weber, Chief Operating Officer (Age 58)
- Mr. Michael G. Howley, VP & GM of Global Sales (Age 55)
- Mr. William J. Bolt, Sr. VP of Global Quality, Regulatory & Clinical Operations (Age 67)
- Mr. Ian McLeod, VP & Corp. Controller
Who are ABIOMED's major shareholders?
ABIOMED's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Scout Investments Inc. (0.22%), Retirement Systems of Alabama (0.19%), Navellier & Associates Inc (0.05%), Nisa Investment Advisors LLC (0.03%), Gulf International Bank UK Ltd (0.02%) and Dorsey Wright & Associates (0.02%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Martin P Sutter, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.
Which major investors are selling ABIOMED stock?
ABMD stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Scout Investments Inc., Dorsey Wright & Associates, Gulf International Bank UK Ltd, Central Bank & Trust Co., Juncture Wealth Strategies LLC, Oakbrook Investments LLC and First Hawaiian Bank. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Martin P Sutter, Michael G Howley, Michael R Minogue and William J Bolt. View Insider Buying and Selling for ABIOMED.
Which major investors are buying ABIOMED stock?
ABMD stock was acquired by a variety of institutional investors in the last quarter, including Retirement Systems of Alabama, QUANTRES ASSET MANAGEMENT Ltd, Sit Investment Associates Inc., Navellier & Associates Inc, Cerebellum GP LLC, State of Alaska Department of Revenue, Ipswich Investment Management Co. Inc. and Gateway Investment Advisers LLC. View Insider Buying and Selling for ABIOMED.
How do I buy shares of ABIOMED?
Shares of ABMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ABIOMED's stock price today?
One share of ABMD stock can currently be purchased for approximately $333.74.
How big of a company is ABIOMED?
ABIOMED has a market capitalization of $15.03 billion and generates $593.75 million in revenue each year. The medical equipment provider earns $112.17 million in net income (profit) each year or $2.45 on an earnings per share basis. ABIOMED employs 1,143 workers across the globe.
What is ABIOMED's official website?
How can I contact ABIOMED?
ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]
MarketBeat Community Rating for ABIOMED (NASDAQ ABMD)
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe ABMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
